Meridian Bioscience
May Lag for Many Dx Firms' Stock Prices as 360Dx Index Drops 4 Percent
Of the 30 companies in the index, 18 firms saw their stock prices decrease, while 12 firms' share prices increased.Â
Meridian Bioscience Fiscal Q2 Revenues Up 49 Percent
Despite the overall revenue increase, revenues from Meridian's diagnostic segment were down 9 percent.
Bucking Downward 2021 Trend, 360Dx Index Rebounds 4 Percent in April
Of the 30 companies in the index, 18 firms saw their stock prices increase, while 12 saw their share prices decline.
NIH RADx Program Awards $29.3M to Increase SARS-CoV-2 Testing Capacity
The contracts are for two lateral flow rapid antigen tests, a laboratory-based test to detect and identify SARS-CoV-2 variants, and a rapid RT-PCR test.
Meridian Bioscience Submits Curian Campylobacter Assay to FDA
The test runs on the firm's Curian rapid fluorescent immunoassay and detects four species of a common foodborne pathogen.